6
Empowering Biotech Innovation in Asia-Pacific

Empowering Biotech Innovation in Asia-Pacific

This report by Bain & Company and J.P.Morgan explores APAC’s rise as a global biotech innovation hub with Singapore as a strategic base for biotech R&D and commercialisation.

Empowering Biotech Innovation in Asia-Pacific masthead

Global pharma is sourcing innovation from the Asia-Pacific (APAC) region, which is gaining relevance in advanced modalities. With the public sector playing a key role in empowering biotech innovation, Singapore – with its commitment to innovation, stability, intellectual property protection and regulatory alignment – is emerging as an APAC biotech leader.

Produced through a collaboration between Bain & Company, A*STAR, EDB, J.P. Morgan, and SG Growth Capital, the report offers insights for biotech and pharma players, as well as APAC policymakers. Read to learn about:

  • Biotech investment trends: Why capital is shifting toward late-stage, lower-risk assets and how public funding is filling early-stage gaps
  • Advanced therapeutics and technology platforms: Asia’s growing strengths in mRNA, cell and gene therapy, antibody-drug conjugates (ADCs), and artificial intelligence-led drug discovery
  • Global pharma strategy: How geopolitical dynamics and tightening US research budgets are pushing pharma to expand R&D and sourcing in Asia
  • How government and the public sector can power biotech ecosystems: These span policy tools, research infrastructure, and talent strategies 
  • Singapore’s advantage: How the country’s neutrality, IP protection, regulatory strength, and infrastructure are attracting top-tier firms and enabling end-to-end innovation

Access the full paper to gain insight into APAC’s evolving role in global biotech hub.

Related Content

Subscribe Icon
The latest business insights and news delivered to your inbox
Subscribe now